RxDoctor Payments Data

Kathryn Oreilly, MD

MOHS-Micrographic Surgery · Lewes, DENPI 1033370408

Payments from drug & device makers

$371in general payments, 2019–2025

Across 9 payments — averaging $41.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$195
  • Arcutis Biotherapeutics, Inc.$60
  • UCB, Inc.$31
  • AbbVie$19
  • Pfizer$18
  • Regeneron Healthcare Solutions, Inc.$17
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$17648%
  • Education$19552%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few mohs-micrographic surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,360,754
Medicare patients
3,324
Services billed
29,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast23$111,815
HumiraAdalimumab13$87,842
Clobetasol Propionate61$4,999
Metronidazole35$2,444
Fluorouracil33$1,892
Ketoconazole73$1,755
Betamethasone Dipropionate19$662
CiclopiroxCiclopirox Olamine13$393
Triamcinolone Acetonide42$335
Clindamycin Phosphate12$304
Mupirocin29$290
ValacyclovirValacyclovir Hcl15$195
Hydrocortisone35$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$16$111,81523 claims
AbbVieHumira$19$87,84213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other mohs-micrographic surgery in Lewes

Where these figures come from

Is this you, or does something look wrong? →